Introduction: Rotational Thromboelastometry (ROTEM) is a point of care method
INTEM and FIBTEM). For this purpose, whole blood samples from 20 healthy donors were spiked in vitro with apixaban, edoxaban, rivaroxaban or dabigatran at 5 different concentrations in plasma (0, 50, 100, 200, 500 and 1000 ng/mL). Thromboelastometric parameters were determined for each concentration for the 3 types of ROTEM tests. Plasma DOAC concentration required to double baseline CT was determined according to the equation obtained from the linear regression between CT and DOAC concentration. a The apixaban concentration required to double baseline INTEM CT is >1200 ng/mL and cannot be precisely calculated (a 1.35-fold mean increase in INTEM CT was observed at 1000 ng/mL).
T A B L E 2 Impact of apixaban, edoxaban, rivaroxaban and dabigatran on ROTEM parameters .713 9.7 ± 3.4 10 (5-13) 
(continues)

| MATERIAL AND METHODS
| Blood collection and ethics statement
| Blood sample spiking
Whole blood samples from 5 healthy donors were spiked with 1 of the 4 DOACs.
For the preparation of the spiking solutions, apixaban, edoxaban and rivaroxaban, all obtained from AlsaChim (Illkirch Graffenstaden, France), were dissolved in Dimethylsulphoxide (DMSO) to prepare a 400 μg/mL stock solution. The stock solution was subsequently diluted the day of the experiment in 150 mmol/L NaCl to obtain a 50 μg/mL DOAC working solution. The working solution was then diluted at 1/50 in an aliquot of whole blood to get a theoretical DOAC concentration of 1000 ng/mL in whole blood (0.25% DMSO). Then, this aliquot was centrifuged at 2500 g for 15 minutes to determine the exact DOAC concentration in plasma. The determination of DOAC plasma level in this aliquot allowed to precisely adjust spiking in 3 mL of whole blood from the same donor to obtain a plasma concentration of ~1000 ng/mL. These 3 mL of blood were then diluted 1:2, 1:5, 1:10 and 1:20 in whole blood from the same donor (without anticoagulant but supplemented with DMSO) to get the same final DMSO concentration in all samples (including controls) to obtain concentrations in plasma of ~500, 200, 100 and 50 ng/mL, respectively.
For preparation of the dabigatran spiking solution, dabigatran obtained from AlsaChim was dissolved in HCl 1N according to manufacturer instructions to prepare a 100 μg/mL dabigatran stock solution.
This solution was subsequently diluted at 1/100 in whole blood the day of the experiment to get a theoretical concentration of 1000 ng/ mL in whole blood. Then, this aliquot was centrifuged at 2500 g for 15 minutes to determine the exact dabigatran plasma concentration. The determination of dabigatran plasma level in this aliquot allowed to precisely adjust spiking in 3 mL of whole blood from the same donor to obtain a plasma concentration of ~1000 ng/mL. These 3 mL of blood were then diluted 1:2, 1:5, 1:10 and 1:20 in whole blood from the same donor (without anticoagulant but supplemented with HCl) to obtain concentrations in plasma of ~500, 200, 100 and 50 ng/mL, respectively.
Aliquots of whole blood spiked with different DOACs concentrations (1000, 500, 200, 100, 50 and 0 ng/mL) were then used for the ROTEM tests. An aliquot of blood was also centrifuged at 2500 g for 15 minutes to determine the DOAC plasma concentration for each dilution. 
| ROTEM tests
| Determination of DOAC plasma concentrations
Apixaban, edoxaban and rivaroxaban plasma concentrations were 
| Statistical analyses
Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software Inc, La Jolla, CA, USA). Paired Wilcoxon rank tests were used to compare ROTEM parameters of samples spiked with DOACs to controls. Two-sided significance tests were used throughout.
Linear regression was performed using EXCEL 2010 software (Microsoft Office).
| Determination of DOAC concentration required to double baseline CT
The equation of the linear regression between CT and DOAC concentration was determined (as a linear relationship was found between
CTs and DOAC concentrations). The equation (CT = a. [DOAC] + b where a is the slop and b is the y-intercept when [DOAC] = 0) was used to calculate the DOAC concentrations require to double baseline
CTs ( Figure 1A ,B and Table 1 ).
| RESULTS
After spiking whole blood samples with anticoagulants, we checked the concentrations in plasma (Table 2) Table 1 . INTEM CT was less sensitive than EXTEM CT to anticoagulant whatever the DOAC (Table 1) .
EXTEM CT was above the normal range (according to the manufacturer's instructions) for 5 of 5 spiked DOAC samples when DOAC concentrations were ~1000 ng/mL for apixaban, ~100 ng/mL for edoxaban and ~200 ng/mL for rivaroxaban and dabigatran (Table 3) .
Otherwise, EXTEM CT was above the normal range for at least 1 of 5 spiked DOAC samples, when concentrations were ~200 ng/mL for .062
11.0 ± 2. 9 10 (8-15) .500 apixaban, and ~50 ng/mL for edoxaban, rivaroxaban and dabigatran (Table 3) .
INTEM CT stayed within the normal range for 4 of 5 samples spiked with apixaban even at the highest concentration (~1000 ng/mL). On the other hand, INTEM CT was above the upper limit of the normal range for 5 of 5 spiked samples when concentrations were ~500 ng/mL for edoxaban, ~500 ng/mL for rivaroxaban and ~200 ng/mL for dabigatran (Table 3) . INTEM CT was above of the upper limit of the normal range for at least 1 of 5 spiked DOAC samples, when concentrations were ~1000 ng/mL for apixaban, ~200 ng/mL for edoxaban and rivaroxaban and ~100 ng/mL for dabigatran (Table 3) .
Direct oral anticoagulants have no significant influence on MCF, alpha angle or CFT whatever the test (EXTEM, INTEM or FIBTEM) (Table 2 ; Figures S1 and S2 ). It should be noted that the mean value of FIBTEM MCF in our 20 healthy subjects (10.1 ± 2.8. mm) was found to be near the lower limit of the normal range (9-25 mm) defined by the manufacturer (2 healthy volunteers, presenting with a low FIBTEM MCF at baseline (5 mm for both), had fibrinogen levels of respectively at 2.1 and 2.3 g/L).
| DISCUSSION
Treatments with DOACs do not require routine laboratory monitoring, except in specific medical settings such as severe bleeding or emergency surgery. 6 Determination of plasma levels of anti-Xa DOACs (apixaban, edoxaban and rivaroxaban) requires specific assays based on anti-Xa chromogenic measurement with specific calibrators. 7, 8 Determination of dabigatran level also requires specialized assays 7 (ie, diluted thrombin time or ecarin assays). Indeed, the usual laboratory parameters, prothrombin time (PT) and activated partial thromboplastin time (aPTT) are neither specific nor sufficiently sensitive for detecting DOACs and quantifying their plasma levels. 7 Results of PT and aPTT may be in the normal range despite significant plasma DOAC levels, in particular with apixaban. 9, 10 Methods able to quickly determine the degree of anticoagulation are needed in patients under DOACs presenting with severe bleeding or requiring urgent surgery. The degree of anticoagulation underlies the management of these patients (ie, delaying surgery or administration of reversing or procoagulant therapeutics).
6,11
The main advantage of ROTEM ® is the rapid availability of results from whole blood at the POC. Whether ROTEM is sensitive to DOACs has previously been only partially investigated for some DOACs and for some tests. Therefore, we designed this comprehensive study to determine the impact of the 4 currently approved DOACs (apixaban, edoxaban, rivaroxaban and dabigatran) on the 3 most usual ROTEM
tests (EXTEM, INTEM and FIBTEM).
Direct oral anticoagulants plasma levels for the prevention of stroke in patients with nonvalvular atrial fibrillation are usually between 100
and 400 ng/mL at peak level [12] [13] [14] Here, we showed a dose-dependent increase in EXTEM CT and in INTEM CT. EXTEM CT was by far more sensitive than INTEM CT whatever the anticoagulant. EXTEM CT was more sensitive to edoxaban than to rivaroxaban and dabigatran which were all far more sensitive than to apixaban. However, EXTEM CT was unable to systematically detect low concentrations (~50 ng/mL) whatever the anticoagulant (Table 3) .
It is well established that PT and aPTT have low sensitivity to apixaban. In the present study, we observed a higher increase in INTEM CT with dabigatran compared to the anti-Xa DOACs. Dabigatran has been shown to induce a higher increase in aPTT than the anti-Xa DOACs. 9, 17 It seems that dabigatran has a higher impact on coagulation times than anti-Xa DOACs when coagulation is triggered by the intrinsic pathway. There are several limitations to be acknowledged in the present study. Firstly, our study is based on in vitro DOAC-spiked samples and not on samples from patients or healthy controls having ingested DOACs. Secondly, the relatively small number of samples tested per DOAC (n = 5) affects the statistic power of our study.
Our study adds new insight on previous studies. To the best of our knowledge, we are the first to compare plasma DOAC concentrations to EXTEM and INTEM CTs for apixaban, edoxaban and dabigatran. Indeed, most studies only reported a dose of medication or a spiked concentration in whole blood without determining plasma concentrations. The impact on MCF was not previously comprehensively reported. Furthermore, the effect of DOACs on the FIBTEM assay has only been poorly evaluated so far. Finally, we report the impact of edoxaban on ROTEM parameters for the first time.
In conclusion, this study found a DOAC dose-dependent increase in ROTEM CTs. CTs were only poorly impacted by low levels of edoxaban, rivaroxaban or dabigatran. Apixaban had a low effect on CT even at high concentrations. No significant impact on MCFs was observed.
These elements must be taken into consideration when interpreting ROTEM assays of patients under DOACs.
